Replies to post #211855 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Something is not right - I agree. That is for a separate discussion. I'm not going to go that route because I'm a firm believer there are some hedge funds that have some illegal holdings in a heavy short way here. My beliefs are my own and I have my reasoning. However a constant drip from Aspire does not help anyone, but it does buy us time and does move us forward. I mean you can't argue Dunn. They have used aspire to complete 8 trials. Mid trials and all have been successful ----- just one left in Prurisol and read outs are weeks away.

The data and the fact the FDA has allowed us to plan and move forward should have this stock over a billion MC.... IMO. Easily.


I think there are so many options outside Aspire to move a phase 3 forward. But I'm also thinking we are over a year in the making of a mega deal and deals take years.... I personally think iPIX has climbed the wall and sits on top .............we just need that one domino to fall and this will be a watershed moment in iPIX history. As I look at the history of companies and the movement of single drugs and single indications and share price increases and the huge gaps on single drugs....iPIX will gap more than anyone has ever seen IMO after the first domino falls. It's time to catch up IMO.

Good luck

[DesireToLearn]

From a late May PR....Additional preliminary data analyses of secondary endpoints show patients who received any dose of Prurisol, regardless of the treatment arm, had a 1-point improvement (using the IGA scoring system) at a higher rate than that of patients in the placebo arm. This is another clear indication of the drug’s efficacy. Increases in Prurisol’s therapeutic response, upon evaluating patients at Day 56 (Week 8) and Day 84 (Week 12) of treatment, also were apparent in the Prurisol 200mg arm, suggesting an improving response over time.

Cellceutix is extremely proud of the Phase 2 Prurisol results. Simply put, the drug’s efficacy compares favorably with many current and various types of treatments for psoriasis (see the study linked to below), including apremilast or Otezla®, which is the leading oral FDA approved anti-psoriasis drug. It is interesting to do a side-by-side comparison between the two based on publicly available literature, and it could be argued that Prurisol performs on par with, if not better than, Otezla® at the identical stage of development

My opinion on favorable factors: oral and earlier impact are 2 big selling points.

[DrBones]

I’d rather we avoid your false rally as you and cronies switch your tune to run up price for a nice 20-40 cent flip. Let’s see results and let a run or decline occur from there.